• J Trauma · May 2003

    Review

    Recent developments in European colloid solutions.

    • Hans-Jürgen Dieterich.
    • Department of Anesthesiology and Intensive Care Medicine, Tuebingen University Hospital, Germany. hjdieter@med.uni-tuebingen.de
    • J Trauma. 2003 May 1;54(5 Suppl):S26-30.

    AbstractCoagulopathy resulting from hydroxyethyl starch (HES) administration is well documented for high-molecular-weight, highly substituted HES solutions. These are the only starch-based synthetic colloids approved for volume replacement in the United States. Recent developments in European colloid solutions revolve around designing new starch molecules. By increasing the C2:C6 ratio and decreasing the molar substitution to 0.4, a new HES with a molecular weight of 130,000 was introduced. This solution is without significant influence on coagulation. Actual experimental work is concentrating on modulating the inflammatory response of monocytes and endothelial cells after infusion of colloid solutions. This may help prevent or even correct capillary leak, and the intravascular persistence of infused colloidal might be prolonged.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!

We guarantee your privacy. Your email address will not be shared.